国际眼科纵览

• 综述 •    下一篇

青光眼手术滤过通道抗瘢痕化的药物研究

于雪婷  孙兴怀   

  1.  200030上海,复旦大学附属眼耳鼻喉科医院眼科
  • 收稿日期:2018-07-08 出版日期:2018-10-22 发布日期:2018-10-25
  • 通讯作者: 孙兴怀,Email: xhsun@shmu.edu.cn

Study on anti-cicatricial treatments for filtration canal after glaucoma surgery

YU Xue-ting, SUN Xing-huai.   

  1. Department of Ophthalmology, EYE & ENT Hospital of Fudan University, Shanghai 200030, China
  • Received:2018-07-08 Online:2018-10-22 Published:2018-10-25
  • Contact: SUN Xing-huai, Email: xhsun@shmu.edu.cn

摘要:

青光眼滤过手术前后预防、抑制滤过道瘢痕形成是影响手术成败的关键。近年青光眼手术滤过通道抗瘢痕化的研究包括非特异性的抗炎抗代谢药物如5-氟尿嘧啶、丝裂霉素C、糖皮质激素等,特异性作用于某个受体或干扰信号通路的药物如抗血管内皮生长因子药物、作用于转化生长因子-β通路的药物等,以及药物载体如可降解胶原基质、γ-环糊精及壳聚糖等。(国际眼科纵览,2018, 42: 289-296)

Abstract:

During the perioperative period of glaucoma filtration surgery, prevention and inhibition of scar formation in filtration canal is the key for long-term success.  Anti-scarring treatments for filtration canal after glaucoma surgery include non-specific anti-inflammatory or anti-metabolite drugs(such as 5-fluorouracil, mitomycin C, glucocorticoids, etc), specific drugs that target certain receptors or interfere signaling pathway(such as anti-vascular endothelial growth factor, drugs acting on transforming factor pathways etc),  as well as drug delivery system(such as degradable collagen matrix, γ-cyclodextrin and chitosan). (Int Rev Ophthalmol, 2018, 42:  289-296)